Evolus, Inc. (EOLS)
NASDAQ: EOLS · Real-Time Price · USD
7.13
-0.02 (-0.28%)
Jun 26, 2026, 4:00 PM EDT - Market closed
Evolus Employees
Evolus had 350 employees as of March 31, 2026. The number of employees increased by 16 or 4.79% since the number was last reported on December 31, 2025.
Employees
350
Change
16
Growth
4.79%
Revenue / Employee
$862,260
Profits / Employee
-$124,066
Market Cap
469.54M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Tilray Brands | 2,842 |
| Canopy Growth | 960 |
| Emergent BioSolutions | 900 |
| Organogenesis Holdings | 854 |
| Kamada | 462 |
| Esperion Therapeutics | 294 |
| Akebia Therapeutics | 194 |
| Alpha Teknova | 158 |
EOLS News
- 16 days ago - Evolus Transcript: AGM 2026 - Transcripts
- 22 days ago - Evolus files $250M mixed securities shelf - TheFly
- 22 days ago - Evolus Registration statement: Registration filing - Filings
- 23 days ago - Evolus management to meet virtually with BTIG - TheFly
- 23 days ago - Evolus Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 5 weeks ago - Evolus to Participate in The Jefferies Global Healthcare Conference - Business Wire
- 6 weeks ago - Evolus announces commercial launch of Estyme in Europe - TheFly
- 6 weeks ago - Evolus Announces Commercial Launch of Estyme® Injectable Hyaluronic Acid Gels in Europe - Business Wire